We found several key anti-tumor Th1 cytokines such as interleukin (IL)-2, IL-4, and interferon-γ, were stimulated by the combination therapy either systemically or in tumors or both, as well as anti-tumor biomarkers such as Granzyme B and perforin. Here, IL4 is linked to neoplasm.